Innoviva (INVA) to Release Earnings on Wednesday

Innoviva (NASDAQ:INVA) is expected to issue its Q1 2026 results before the market opens on Wednesday, May 6th. Analysts expect the company to announce earnings of $0.43 per share and revenue of $101.5650 million for the quarter. Investors may review the information on the company’s upcoming Q1 2026 earning report for the latest details on the call scheduled for Thursday, May 7, 2026 at 4:00 PM ET.

Innoviva (NASDAQ:INVA) last released its earnings results on Wednesday, February 25th. The biotechnology company reported $1.94 EPS for the quarter, topping analysts’ consensus estimates of $0.34 by $1.60. Innoviva had a net margin of 65.92% and a return on equity of 37.63%. The company had revenue of $114.61 million during the quarter, compared to analysts’ expectations of $102.62 million. On average, analysts expect Innoviva to post $2 EPS for the current fiscal year and $2 EPS for the next fiscal year.

Innoviva Trading Up 1.4%

Shares of Innoviva stock opened at $23.69 on Wednesday. The company has a current ratio of 14.64, a quick ratio of 13.85 and a debt-to-equity ratio of 0.22. Innoviva has a 12-month low of $16.52 and a 12-month high of $25.15. The firm has a market capitalization of $1.75 billion, a price-to-earnings ratio of 7.77 and a beta of 0.40. The firm’s 50 day simple moving average is $23.03 and its two-hundred day simple moving average is $21.12.

Analyst Ratings Changes

INVA has been the topic of several research reports. BTIG Research reissued a “buy” rating and issued a $35.00 target price on shares of Innoviva in a research report on Thursday, February 26th. Weiss Ratings reaffirmed a “buy (b)” rating on shares of Innoviva in a research report on Friday, March 27th. Five equities research analysts have rated the stock with a Buy rating, one has given a Hold rating and one has issued a Sell rating to the company. According to data from MarketBeat.com, the stock presently has an average rating of “Moderate Buy” and an average target price of $34.80.

Hedge Funds Weigh In On Innoviva

A number of institutional investors have recently modified their holdings of the stock. Royal Bank of Canada grew its holdings in Innoviva by 81.1% during the first quarter. Royal Bank of Canada now owns 21,530 shares of the biotechnology company’s stock worth $389,000 after acquiring an additional 9,639 shares during the period. AQR Capital Management LLC lifted its holdings in Innoviva by 17.8% in the first quarter. AQR Capital Management LLC now owns 167,456 shares of the biotechnology company’s stock valued at $3,036,000 after acquiring an additional 25,317 shares during the period. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. lifted its holdings in Innoviva by 4.4% in the first quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 32,882 shares of the biotechnology company’s stock valued at $596,000 after acquiring an additional 1,392 shares during the period. NewEdge Advisors LLC purchased a new stake in Innoviva in the 1st quarter worth approximately $243,000. Finally, UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC grew its stake in shares of Innoviva by 21.9% during the 1st quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC now owns 171,116 shares of the biotechnology company’s stock worth $3,102,000 after purchasing an additional 30,792 shares during the period. Hedge funds and other institutional investors own 99.12% of the company’s stock.

Innoviva Company Profile

Innoviva, Inc, incorporated in Delaware and headquartered in San Francisco, California, is a royalty-focused life sciences company. It acquires, manages and monetizes royalty and license interests in biopharmaceutical products, with a primary emphasis on inhaled respiratory therapies. Innoviva’s portfolio is anchored by royalties on therapies originally developed by its former affiliate, now marketed by GlaxoSmithKline, including several long-acting inhaled products approved for chronic obstructive pulmonary disease (COPD) and asthma.

The company was established through a spin?out transaction in 2014, separating the royalty assets from a research?based biopharmaceutical enterprise to create a specialized investment vehicle.